Show newer


• This was the first randomized, double-blinded, placebo-controlled clinical trial evaluating outpatients with mild COVID-19

• Viral clearance rates within a 9-day period from symptom onset did not change with hydroxychloroquine and azithromycin (HCQ/AZT) treatment

• The use of HCQ/AZT combination was safe and not associated with more adverse effects or major cardiovascular events

Show thread

Une étude randomisée en double aveugle contre placebo sur l’efficacité de l’association hydroxychloroquine/azithromycine sur la diminution de la charge virale.

This service is offered by alarig.
Beer, privacy and free software lovers. Join us!